Epizyme, Inc. Sustainability Profile
Epizyme, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2008, Epizyme has made significant strides in the field of epigenetics, focusing on the discovery and development of small molecule drugs that target specific genetic mutations. The company’s flagship product, Tazemetostat, is a first-in-class EZH2 inhibitor that has garnered attention for its unique mechanism of action and potential to treat various malignancies. With a strong commitment to advancing precision medicine, Epizyme has established a notable market position, particularly in the oncology sector, and continues to expand its pipeline of targeted therapies. Through its dedication to scientific excellence, Epizyme is shaping the future of cancer treatment and improving patient outcomes.
DitchCarbon Score
How does Epizyme, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Epizyme, Inc.'s score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Epizyme, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Ipsen S.A., which means that any climate commitments or emissions data may be inherited from its parent organisation. As a subsidiary, Epizyme's climate initiatives and targets are aligned with those of Ipsen S.A. However, specific reduction targets or achievements for Epizyme itself have not been disclosed. The company does not have any documented reduction targets or climate pledges at this time. For context, Ipsen S.A. has established various climate initiatives, which may influence Epizyme's approach to sustainability and emissions management. As of now, Epizyme's commitment to addressing climate change remains vague, with no specific metrics or targets available for public review.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 14,316,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 4,343,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 121,718,000 | 00,000,000 | 00,000,000 | - | 00,000,000 |
How Carbon Intensive is Epizyme, Inc.'s Industry?
How Carbon Intensive is Epizyme, Inc.'s Location?
Epizyme, Inc.'s Scope 3 Categories Breakdown
Epizyme, Inc.'s Scope 3 emissions, which increased by 405% last year and decreased by approximately 25% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 67% of Scope 3 emissions.
Top Scope 3 Categories
Epizyme, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Epizyme, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
